ClinicalTrials.gg
CompletedNCT02100475DUAL™Updated Jan 20, 2017Results posted

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification

A Phase 3 interventional study of insulin degludec/liraglutide and insulin aspart in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 60 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-20.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
64th of 70
31 · median 384
Started
2014
with 2 others
Phase 3
49 of 70
2 open now
Registered
41st of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 64th largest by enrollment, is one of 3 that started in 2014, is one of 49 in phase 3, and was the 41st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted globally. The aim of the trial is to compare sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously treated with insulin degludec/liraglutide and metformin and in need of further intensification.

This is an extension to trial NN9068-3952, NCT01952145 (DUAL™ V).

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 31 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion (Visit 28) of NN9068-3952 with insulin degludec/liraglutide + metformin
  • (glycosylated ) above or equal to 7 percent at Visit 27 of NN9068-3952 trial

Exclusion criteria

Exclusion Criteria:

  • diseases of the major organ systems
  • Screening calcitonin above or equal to 50 ng/L
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Insulin degludec/liraglutide + Metformin

    Drug: insulin degludec/liraglutide

  • Active comparator
    Insulin degludec/liraglutide + Insulin Aspart + Metformin

    Drug: insulin degludec/liraglutide · Drug: insulin aspart

Interventions

  • Druginsulin degludec/liraglutide

    Drug pages: Insulin degludec · Liraglutide

    Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin. Dose individually adjusted.

  • Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (Glycosylated Haemoglobin)

    Change from baseline in HbA1c after 26 weeks of treatment.

    Time frame: Week 0, week 26

Secondary outcomes

  1. Change From Baseline in Body Weight

    Change from baseline in body weight after 26 weeks of treatment.

    Time frame: Week 0, week 26

  2. Number of Treatment-emergent Confirmed Hypoglycaemic Episodes

    Treatment-emergent hypoglycaemic episodes: if the onset of the episode occurred on or after the first day of investigational medicinal product administration, and no later than 7 days after the last day on investigational medicinal product. Confirmed hypoglycaemia: subject unable to treat himself/herself and/or have a recorded plasma glucose \< 3.1 mmol/L (56 mg/dL).

    Time frame: Week 0 - 26

08

Results

Posted Jan 20, 2017
Limitations and caveats
Due to the small number of subjects in this trial, the data should be interpreted with caution.

Participant flow

The trial was conducted at 19 sites in 8 countries as follows: Argentina: 2 sites; Greece: 2 sites, Hungary: 1 site; Russian Federation: 5 sites; Slovakia: 4 sites, South Africa: 1 site; Spain: 1 site, United States: 3 sites.

Participant flow — Overall Study
MilestoneIDegLiraIDegLira + IAsp
Started1615
Completed1413
Not completed22
Withdrew: Unclassified12
Withdrew: Withdrawal criteria10

Outcome measures

PrimaryChange From Baseline in HbA1c (Glycosylated Haemoglobin)

Change from baseline in HbA1c after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · Percentage of glycosylated haemoglobin
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Percentage of glycosylated haemoglobinIDegLiraIDegLira + IAsp
Change From Baseline in HbA1c (Glycosylated Haemoglobin)-0.43 ± 0.94-0.14 ± 1.09
Statistical analysis
  • IDegLira vs IDegLira + IAsp · ANCOVA · p = 0.427 · Mean difference (final values): -0.3 · 95% CI -1.05 to 0.46
SecondaryChange From Baseline in Body Weight

Change from baseline in body weight after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · Kilograms
Change From Baseline in Body Weight
KilogramsIDegLiraIDegLira + IAsp
Change From Baseline in Body Weight0.9 ± 2.11.5 ± 3.2
SecondaryNumber of Treatment-emergent Confirmed Hypoglycaemic Episodes

Treatment-emergent hypoglycaemic episodes: if the onset of the episode occurred on or after the first day of investigational medicinal product administration, and no later than 7 days after the last day on investigational medicinal product. Confirmed hypoglycaemia: subject unable to treat himself/herself and/or have a recorded plasma glucose \< 3.1 mmol/L (56 mg/dL).

Time frame:
Week 0 - 26
Reported as:
Number · Number of episodes
Number of Treatment-emergent Confirmed Hypoglycaemic Episodes
Number of episodesIDegLiraIDegLira + IAsp
Number of Treatment-emergent Confirmed Hypoglycaemic Episodes344

Adverse events

Collected over From first trial-related activity (week 0) after the subject had signed the informed consent until the end of the post-treatment follow-up period (week 27).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDegLira—1/16 (6.3%)11/16 (68.8%)
IDegLira + IAsp—2/15 (13.3%)3/15 (20%)
Most frequent serious events
Most frequent serious events
EventIDegLiraIDegLira + IAsp
Chronic myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/161/15
Renal failureRenal and urinary disorders0/161/15
Acute coronary syndromeCardiac disorders1/160/15
Coronary revascularisationSurgical and medical procedures1/160/15
Most frequent other events
Showing 10 of 26
Most frequent other events
EventIDegLiraIDegLira + IAsp
Abdominal painGastrointestinal disorders0/161/15
Amylase increasedInvestigations0/161/15
AsthmaRespiratory, thoracic and mediastinal disorders0/161/15
Back painMusculoskeletal and connective tissue disorders1/161/15
Cardiac murmurInvestigations0/161/15
DiarrhoeaGastrointestinal disorders0/161/15
HyperkalaemiaMetabolism and nutrition disorders0/161/15
Lipase increasedInvestigations1/161/15
Oedema peripheralGeneral disorders0/161/15
Renal cystRenal and urinary disorders0/161/15

Baseline characteristics

Baseline characteristics were presented for full analysis set (FAS = 31 subjects).

Age, Continuous
Age, Continuous(Years)IDegLiraIDegLira + IAspTotal
Mean57.3 ± 11.757.4 ± 11.257.4 ± 11.3
Gender
Gender(Participants)IDegLiraIDegLira + IAspTotal
Female9817
Male7714
HbA1c
HbA1c(Percentage of glycosylated haemoglobin)IDegLiraIDegLira + IAspTotal
Mean7.6 ± 0.97.7 ± 0.77.6 ± 0.8
09

Study locations

60 sites
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    Fort Lauderdale, Florida 33316-2521, United States
  • Novo Nordisk Investigational Site
    Gurnee, Illinois 60031, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Slidell, Louisiana 70461-4231, United States
  • Novo Nordisk Investigational Site
    Altoona, Pennsylvania 16602, United States
  • Novo Nordisk Investigational Site
    Renton, Washington 98057, United States
  • Novo Nordisk Investigational Site
    Buenos Aires, B1704ETD, Argentina
  • Novo Nordisk Investigational Site
    Capital Federal, C1056ABJ, Argentina
  • Novo Nordisk Investigational Site
    Corrientes, 3400, Argentina
  • Novo Nordisk Investigational Site
    Salta, 4400, Argentina
  • Novo Nordisk Investigational Site
    Zarate, B2800DGH, Argentina
  • Novo Nordisk Investigational Site
    Wollongong, New South Wales 2500, Australia
  • Novo Nordisk Investigational Site
    Herston, Queensland 4029, Australia
  • Novo Nordisk Investigational Site
    Ipswich, Queensland 4305, Australia
  • Novo Nordisk Investigational Site
    Robina, Queensland 4226, Australia
  • Novo Nordisk Investigational Site
    East Ringwood, Victoria 3135, Australia
  • Novo Nordisk Investigational Site
    Athens, GR-11527, Greece
  • Novo Nordisk Investigational Site
    Ioannina, 45500, Greece
  • Novo Nordisk Investigational Site
    Larissa, GR-41110, Greece
  • Novo Nordisk Investigational Site
    Thessaloniki, GR-54642, Greece
  • Novo Nordisk Investigational Site
    Thessaloniki, GR-57001, Greece
  • Novo Nordisk Investigational Site
    Eger, 3300, Hungary
  • Novo Nordisk Investigational Site
    Gyor, 9024, Hungary
  • Novo Nordisk Investigational Site
    Gyula, 5700, Hungary
  • Novo Nordisk Investigational Site
    Miskolc, 3526, Hungary
  • Novo Nordisk Investigational Site
    Pachuca, Hidalgo 42084, Mexico
  • Novo Nordisk Investigational Site
    Cuernavaca, Morelos 62250, Mexico
  • Novo Nordisk Investigational Site
    Mexico City, México, D.F. 03300, Mexico
  • Novo Nordisk Investigational Site
    Monterrey, 64460, Mexico
  • Novo Nordisk Investigational Site
    Kazan, 420073, Russian Federation
  • Novo Nordisk Investigational Site
    Kirov, 610014, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 117036, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 123448, Russian Federation
  • Novo Nordisk Investigational Site
    Novosibirsk, 630117, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 194358, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 199034, Russian Federation
  • Novo Nordisk Investigational Site
    St. Petersburg, 194354, Russian Federation
  • Novo Nordisk Investigational Site
    Tomsk, 634034, Russian Federation
  • Novo Nordisk Investigational Site
    Tomsk, 634041, Russian Federation
  • Novo Nordisk Investigational Site
    Volgograd, 400131, Russian Federation
  • Novo Nordisk Investigational Site
    Bardejov, 08501, Slovakia
  • Novo Nordisk Investigational Site
    Dolny Kubin, 02601, Slovakia
  • Novo Nordisk Investigational Site
    Kosice, 040 11, Slovakia
  • Novo Nordisk Investigational Site
    Levice, 93401, Slovakia
  • Novo Nordisk Investigational Site
    Poprad, 05801, Slovakia
  • Novo Nordisk Investigational Site
    Povazska Bystrica, 01701, Slovakia
  • Novo Nordisk Investigational Site
    Prievidza, 97101, Slovakia
  • Novo Nordisk Investigational Site
    Trnava, 91701, Slovakia
  • Novo Nordisk Investigational Site
    Velky Meder, 93201, Slovakia
  • Novo Nordisk Investigational Site
    Midrand, Gauteng 1685, South Africa
  • Novo Nordisk Investigational Site
    Durban, KwaZulu-Natal 4450, South Africa
  • Novo Nordisk Investigational Site
    Brits, North West 0250, South Africa
  • Novo Nordisk Investigational Site
    Alberton, 1449, South Africa
  • Novo Nordisk Investigational Site
    Almería, 04001, Spain
  • Novo Nordisk Investigational Site
    Granada, 18012, Spain
  • Novo Nordisk Investigational Site
    Palma de Mallorca, 07014, Spain
  • Novo Nordisk Investigational Site
    Sevilla, 41003, Spain
  • Novo Nordisk Investigational Site
    Sevilla, 41010, Spain
  • Novo Nordisk Investigational Site
    Valencia, 46026, Spain
10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 9 months after primary completion. A results delay was requested in Nov 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2014
First posted
Apr 1, 2014
Start
Apr 2014
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results delay requested
Nov 10, 2016
Results first posted
Jan 20, 2017
Last update
Jan 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02100475
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 1, 2014
Start date
Apr 2014
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Jan 20, 2017
Last update
Jan 20, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion